AUCKLAND, NEW ZEALAND and MELBOURNE, AUSTRALIA--(MARKET WIRE)--Sep 12, 2007 -- Living Cell Technologies Ltd. (ASX:LCT.AX - News) (Other OTC:LVCLF.PK - News) today announced that it has received New Zealand Regional Ethics Committee approval to commence a Phase I/IIa clinical trial of its DiabeCell® product for type I diabetes.
